1. WoodsRS, O'ReganEM, KennedyS, MartinC, O'LearyJJ, et al. (2014) Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review. World J Clin Cases 2: 172–193.
2. FrazerIH, LeggattGR, MattarolloSR (2011) Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol 29: 111–138.
3. GalliSJ, TsaiM (2012) IgE and mast cells in allergic disease. Nat Med 18: 693–704.
4. SayedBA, ChristyA, QuirionMR, BrownMA (2008) The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol 26: 705–739.
5. KobayashiA, GreenblattRM, AnastosK, MinkoffH, MassadLS, et al. (2004) Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 64: 6766–6774.
6. BergotAS, KassianosA, FrazerIH, MittalD (2011) New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) 3: 3461–3495.
7. MunozN, BoschFX, de SanjoseS, HerreroR, CastellsagueX, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–527.
8. ChoyceA, YongM, NarayanS, MattarolloSR, LiemA, et al. (2013) Expression of a single, viral oncoprotein in skin epithelium is sufficient to recruit lymphocytes. PloS one 8: e57798.
9. FiorenzaS, KennaTJ, ComerfordI, McCollS, SteptoeRJ, et al. (2012) A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin. J Immunol 189: 5622–5631.
10. MattarolloSR, YongM, GosmannC, ChoyceA, ChanD, et al. (2011) NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins. J Immunol 187: 1601–1608.
11. RahimpourA, MattarolloSR, YongM, LeggattGR, SteptoeRJ, et al. (2012) gammadelta T cells augment rejection of skin grafts by enhancing cross-priming of CD8 T cells to skin-derived antigen. J Invest Dermatol 132: 1656–1664.
12. MattarolloSR, RahimpourA, ChoyceA, GodfreyDI, LeggattGR, et al. (2010) Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. J Immunol 184: 1242–1250.
13. ChanCY, St JohnAL, AbrahamSN (2013) Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 38: 349–359.
14. GalliSJ, GrimbaldestonM, TsaiM (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8: 478–486.
15. GrimbaldestonMA, NakaeS, KalesnikoffJ, TsaiM, GalliSJ (2007) Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 8: 1095–1104.
16. Leveson-GowerDB, SegaEI, KalesnikoffJ, FlorekM, PanY, et al. (2013) Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. Blood 122: 3659–3665.
17. CoussensLM, RaymondWW, BergersG, Laig-WebsterM, BehrendtsenO, et al. (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382–1397.
18. BalsitisS, DickF, LeeD, FarrellL, HydeRK, et al. (2005) Examination of the pRb-dependent and pRb-independent functions of E7 in vivo. J Virol 79: 11392–11402.
19. KambeN, KambeM, KochanJP, SchwartzLB (2001) Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. Blood 97: 2045–2052.
20. ShamlooA, ManchandiaM, FerreiraM, ManiM, NguyenC, et al. (2013) Complex chemoattractive and chemorepellent Kit signals revealed by direct imaging of murine mast cells in microfluidic gradient chambers. Integr Biol (Camb) 5: 1076–1085.
21. GrimbaldestonMA, ChenCC, PiliponskyAM, TsaiM, TamSY, et al. (2005) Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 167: 835–848.
22. NigrovicPA, GrayDH, JonesT, HallgrenJ, KuoFC, et al. (2008) Genetic inversion in mast cell-deficient (Wsh) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am J Pathol 173: 1693–1701.
23. Schafer B, Piliponsky AM, Oka T, Song CH, Gerard NP, et al. (2013) Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice. J Allergy Clin Immunol 131: 541–548 e541–549.
24. DudeckA, DudeckJ, ScholtenJ, PetzoldA, SurianarayananS, et al. (2011) Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 34: 973–984.
25. MaurerM, WedemeyerJ, MetzM, PiliponskyAM, WellerK, et al. (2004) Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432: 512–516.
26. KhazaieK, BlatnerNR, KhanMW, GounariF, GounarisE, et al. (2011) The significant role of mast cells in cancer. Cancer Metastasis Rev 30: 45–60.
27. BoermaM, FiserWP, HoytG, BerryGJ, JosephL, et al. (2007) Influence of mast cells on outcome after heterotopic cardiac transplantation in rats. Transpl Int 20: 256–265.
28. de VriesVC, Pino-LagosK, NowakEC, BennettKA, OlivaC, et al. (2011) Mast cells condition dendritic cells to mediate allograft tolerance. Immunity 35: 550–561.
29. LuLF, LindEF, GondekDC, BennettKA, GleesonMW, et al. (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442: 997–1002.
30. AndreuP, JohanssonM, AffaraNI, PucciF, TanT, et al. (2010) FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17: 121–134.
31. TranT, BarlowB, O'RearL, JarvisB, LiZ, et al. (2011) Loss of the alpha2beta1 integrin alters human papilloma virus-induced squamous carcinoma progression in vivo and in vitro. PLoS One 6: e26858.
32. HalovaI, DraberovaL, DraberP (2012) Mast cell chemotaxis - chemoattractants and signaling pathways. Front Immunol 3: 119.
33. HuangB, LeiZ, ZhangGM, LiD, SongC, et al. (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112: 1269–1279.
34. OkayamaY, KawakamiT (2006) Development, migration, and survival of mast cells. Immunol Res 34: 97–115.
35. ChenCC, GrimbaldestonMA, TsaiM, WeissmanIL, GalliSJ (2005) Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci U S A 102: 11408–11413.
36. CoussensLM, HanahanD, ArbeitJM (1996) Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 149: 1899–1917.
37. RuffellB, AffaraNI, CottoneL, JunankarS, JohanssonM, et al. (2013) Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 27: 2086–2098.
38. PiliponskyAM, ChenCC, GrimbaldestonMA, Burns-GuydishSM, HardyJ, et al. (2010) Mast cell-derived TNF can exacerbate mortality during severe bacterial infections in C57BL/6-KitW-sh/W-sh mice. Am J Pathol 176: 926–938.
39. LeeJO, RussoAA, PavletichNP (1998) Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391: 859–865.
40. MattarolloSR, YongM, TanL, FrazerIH, LeggattGR (2010) Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen. J Immunol 184: 5663–5669.
41. DanoffTM, LalleyPA, ChangYS, HeegerPS, NeilsonEG (1994) Cloning, genomic organization, and chromosomal localization of the Scya5 gene encoding the murine chemokine RANTES. J Immunol 152: 1182–1189.
42. Kleine-LowinskiK, RheinwaldJG, FichorovaRN, AndersonDJ, BasileJ, et al. (2003) Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer 107: 407–415.
43. CirilliA, SimeoneP, MullerA, BagnatoA, VenutiA (2004) Targeting endothelin receptor type A in human cervical carcinoma cells. J Cardiovasc Pharmacol 44 Suppl 1S72–75.
44. BagnatoA, LoizidouM, PflugBR, CurwenJ, GrowcottJ (2011) Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 163: 220–233.
45. HartPH, GrimbaldestonMA, SwiftGJ, JaksicA, NoonanFP, et al. (1998) Dermal mast cells determine susceptibility to ultraviolet B-induced systemic suppression of contact hypersensitivity responses in mice. J Exp Med 187: 2045–2053.
46. de VriesVC, ElguetaR, LeeDM, NoelleRJ (2010) Mast cell protease 6 is required for allograft tolerance. Transplant Proc 42: 2759–2762.
47. GalliSJ, KalesnikoffJ, GrimbaldestonMA, PiliponskyAM, WilliamsCM, et al. (2005) Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23: 749–786.
48. DaltonDK, NoelleRJ (2012) The roles of mast cells in anticancer immunity. Cancer Immunol Immunother 61: 1511–1520.
49. PittoniP, TripodoC, PiconeseS, MauriG, ParenzaM, et al. (2011) Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 71: 5987–5997.
50. WilkM, LiszkaL, PalenP, GabrielA, LaudanskiP (2010) Intensity of angiogenesis and mast cell infiltration in cervical intraepithelial and invasive lesions - are they correlated? Pathol Res Pract 206: 217–222.
51. HodgesK, KennedyL, MengF, AlpiniG, FrancisH (2012) Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings. Transl Gastrointest Cancer 1: 138–150.
52. TanakaT, IshikawaH (2013) Mast cells and inflammation-associated colorectal carcinogenesis. Semin Immunopathol 35: 245–254.
53. StrouchMJ, CheonEC, SalabatMR, KrantzSB, GounarisE, et al. (2010) Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res 16: 2257–2265.
54. GrimbaldestonMA, SimpsonA, Finlay-JonesJJ, HartPH (2003) The effect of ultraviolet radiation exposure on the prevalence of mast cells in human skin. The British journal of dermatology 148: 300–306.
55. KempTJ, HildesheimA, SafaeianM, DaunerJG, PanY, et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011–2014.
56. VillaLL, CostaRL, PettaCA, AndradeRP, PaavonenJ, et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459–1466.
57. VinzonSE, Braspenning-WeschI, MullerM, GeisslerEK, NindlI, et al. (2014) Protective Vaccination against Papillomavirus-Induced Skin Tumors under Immunocompetent and Immunosuppressive Conditions: A Preclinical Study Using a Natural Outbred Animal Model. PLoS Pathog 10: e1003924.
58. FrazerIH (2004) Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4: 46–54.
59. TrimbleCL, FrazerIH (2009) Development of therapeutic HPV vaccines. Lancet Oncol 10: 975–980.
60. O'BrienPM, Saveria CampoM (2002) Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res 88: 103–117.
61. FridlenderZG, BuchlisG, KapoorV, ChengG, SunJ, et al. (2010) CCL2 blockade augments cancer immunotherapy. Cancer Res 70: 109–118.
62. QianBZ, LiJ, ZhangH, KitamuraT, ZhangJ, et al. (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222–225.
63. HuangB, LeiZ, ZhaoJ, GongW, LiuJ, et al. (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252: 86–92.
64. Yip KH, Kolesnikoff N, Yu C, Hauschild N, Taing H, et al. (2014) Mechanisms of vitamin D(3) metabolite repression of IgE-dependent mast cell activation. J Allergy Clin Immunol 133: 1356–1364, 1364 e1351–1314.